University of Pisa

Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes

a month ago

• Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. • Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. • Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.

TACE Plus Camrelizumab and Rivoceranib Improves PFS in Unresectable HCC

4 months ago

• The CARES-005 study demonstrated that adding camrelizumab and rivoceranib to TACE significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC). • Median PFS was 10.8 months with TACE plus camrelizumab and rivoceranib, compared to 3.2 months with TACE alone (HR 0.34, P<0.0001) at a median follow-up of 13.6 months. • Objective response and disease control rates were also higher in the TACE-CR group, indicating enhanced antitumor efficacy with the combination therapy. • The safety profile of the combination was manageable, with adverse events consistent with those known for TACE, camrelizumab, and rivoceranib.

Low-Dose Triple Combination Pill Shows Superior Blood Pressure Control in Landmark Trial

9 months ago

• A novel low-dose, three-in-one pill (GMRx2) significantly outperformed standard hypertension care in a Nigerian clinical trial. • The GMRx2 group achieved an 81% blood pressure control rate after one month, compared to 55% in the standard care group. • After six months, the GMRx2 group showed a 5.8 mmHg greater reduction in home systolic blood pressure compared to standard care. • George Medicines has submitted GMRx2 to the FDA for hypertension treatment, potentially impacting cardiovascular disease rates globally.